Bulk Manufacturer of Controlled Substances Application: Noramco Inc., 67374-67375 [2020-23396]
Download as PDF
<![CDATA[
67374
Federal Register / Vol. 85, No. 205 / Thursday, October 22, 2020 / Notices
incorporating the same, and any
associated hardware, software, and/or
firmware enabling digital video
capabilities; (b) digital video-capable
displays containing such components;
and (c) digital video-capable computers
containing such components’’;
(3) Pursuant to Commission Rule
210.50(b)(1), 19 CFR 210.50(b)(1), the
presiding administrative law judge shall
take evidence or other information and
hear arguments from the parties and
other interested persons with respect to
the public interest in this investigation,
as appropriate, and provide the
Commission with findings of fact and a
recommended determination on this
issue, which shall be limited to the
statutory public interest factors set forth
in 19 U.S.C. 1337(d)(1) and (f)(1);
(4) For the purpose of the
investigation so instituted, the following
are hereby named as parties upon which
this notice of investigation shall be
served:
(a) The complainants are:
Koninklijke Philips N.V., High Tech
Campus 5, 5656 AE Eindhoven,
Netherlands
Philips North America LLC, 222 Jacobs
Street, Cambridge, Massachusetts
02141
(b) The respondents are the following
entities alleged to be in violation of
section 337, and are the parties upon
which the complaint is to be served:
Dell Technologies Inc., One Dell Way,
Round Rock, Texas 78682–7000
Dell Inc., One Dell Way, Round Rock,
Texas 78682–7000
Hisense Co. Ltd., Hisense Tower, No. 17
Donghaixi Road, South District,
Qingdao, Shandong Province 266071,
China
Hisense Visual Technology Co., Ltd. (f/
k/a Qingdao Hisense Electric Co.,
Ltd.), No. 218 Qianwangang Road,
Qingdao Economic & Technological
Development Zone, Qingdao,
Shandong Province 266555, China
Hisense Electronics Manufacturing,
Company of America Corporation,
7310 McGinnis Ferry Road, Suwanee,
GA 20024
Hisense USA Corporation, 7310
McGinnis Ferry Road, Suwanee, GA
20024
Hisense Import & Export Co. Ltd.,
Hisense Tower, No. 17 Donghaixi
Road, South District, Qingdao,
Shandong Province 266071, China
Hisense International Co., Ltd., Hisense
Tower, Floor 22, No. 17 Donghaixi
Road, South District, Qingdao,
Shandong Province 266071, China
Hisense International (HK) Co., Ltd.,
Room 3101–3105, Singga Commercial
Centre, No. 148 Connaught Road
West, Sheung Wan, Hong Kong (SAR)
VerDate Sep<11>2014
17:35 Oct 21, 2020
Jkt 253001
Hisense International (Hong Kong)
America Investment Co., Ltd., Room
3101–3105, Singga Commercial
Centre, No. 148 Connaught Road
West, Sheung Wan, Hong Kong (SAR)
HP, Inc., 1501 Page Mill Rd., Palo Alto,
CA 94304–1126
Lenovo Group Ltd., Lincoln House, 23rd
Floor, Taikoo Place, 979 King’s Road,
Quarry Bay, Hong Kong (SAR)
Lenovo (United States), Inc., 8001
Development Drive, Morrisville, NC
27560
LG Electronics, Inc., LG Twin Towers,
128, Yeoui-daero, Yeongdeungpo-gu,
Seoul, Republic of Korea, 07736
LG Electronics USA, Inc., 1000 Sylvan
Avenue, Englewood Cliffs, NJ 07632
TCL Industries Holdings Co., Ltd., 9
Floor, TCL Electronics Holdings
Limited Building, TCL International E
City, #1001 Zhongshan Park Road,
Nanshan District, Shenzhen,
Guangdong, 518067, China
TCL Electronics Holdings Ltd. (f/k/a
TCL Multimedia Technology
Holdings Ltd.) 7/F, TCL Building, 22
Science Park E, Hong Kong Science
Park, Hong Kong (SAR)
TCL King Electrical Appliances
(Huizhou) Co. Ltd. No. 78 Zhongkai
Development Zone, Huizhou, 516006,
China
TTE Technology, Inc., 555 South
Promenade Avenue, Suite 103,
Corona, CA 92881
TCL Moka International Ltd., 7/F Hong
Kong Science Park, Bldg. 22 E, 22
Science Park East Avenue, Sha Tin,
Hong Kong
TCL Moka Manufacturing S.A. de C.V.,
Calle 4ta, No. 55, Cd. Industrial,
22444 Tijuana, B.C., Mexico
TCL Smart Device (Vietnam) Company
Ltd, No. 26 VSIP II–A, Street 32,
Vietnam Singapore Industrial Park II–
A Tan Binh Commune, Bac Tan Uyen
District, Binh Duong Province, 75000,
Vietnam
MediaTek Inc., No. 1, Dusing 1st Road,
Hsinchu Science Park, Hsinchu,
30078 Taiwan
MediaTek USA Inc., 2840 Junction
Avenue, San Jose, CA 95134
Realtek Semiconductor Corp., No. 2,
Innovation Road II, Hsinchu Science
Park, Hsinchu 300, Taiwan
Intel Corporation, 2200 Mission College
Boulevard, Santa Clara, CA 95054
(c) The Office of Unfair Import
Investigations, U.S. International Trade
Commission, 500 E Street SW, Suite
401, Washington, DC 20436; and
(5) For the investigation so instituted,
the Chief Administrative Law Judge,
U.S. International Trade Commission,
shall designate the presiding
Administrative Law Judge.
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
Responses to the complaint and the
notice of investigation must be
submitted by the named respondents in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(e) and 210.13(a), as
amended in 85 FR 15798 (March 19,
2020), such responses will be
considered by the Commission if
received not later than 20 days after the
date of service by the complainant of the
complaint and the notice of
investigation. Extensions of time for
submitting responses to the complaint
and the notice of investigation will not
be granted unless good cause therefor is
shown.
Failure of a respondent to file a timely
response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.
By order of the Commission.
Issued: October 16, 2020.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2020–23358 Filed 10–21–20; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–734]
Bulk Manufacturer of Controlled
Substances Application: Noramco Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Noramco Inc. has applied to
be registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before December 21, 2020. Such
persons may also file a written request
SUMMARY:
E:\FR\FM\22OCN1.SGM
22OCN1
67375
Federal Register / Vol. 85, No. 205 / Thursday, October 22, 2020 / Notices
for a hearing on the application on or
before December 21, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
In
accordance with 21 CFR 1301.33(a), this
is notice that on October 6, 2020,
SUPPLEMENTARY INFORMATION:
Noramco Inc. 500 Swedes Landing
Road, Wilmington, Delaware 19801–
4417, applied to be registered as an bulk
manufacturer of the following basic
class(es) of controlled substance(s):
Controlled substance
Drug code
Marihuana ........................................................................................................................................................................
Tetrahydrocannabinols ....................................................................................................................................................
Codeine-N-oxide ..............................................................................................................................................................
Dihydromorphine .............................................................................................................................................................
Hydromorphinol ...............................................................................................................................................................
Morphine-N-oxide ............................................................................................................................................................
Amphetamine ...................................................................................................................................................................
Lisdexamfetamine ............................................................................................................................................................
Methylphenidate ..............................................................................................................................................................
Nabilone ...........................................................................................................................................................................
Phenylacetone .................................................................................................................................................................
Codeine ...........................................................................................................................................................................
Dihydrocodeine ................................................................................................................................................................
Oxycodone .......................................................................................................................................................................
Hydromorphone ...............................................................................................................................................................
Hydrocodone ...................................................................................................................................................................
Morphine ..........................................................................................................................................................................
Oripavine .........................................................................................................................................................................
Thebaine ..........................................................................................................................................................................
Opium extracts ................................................................................................................................................................
Opium fluid extract ..........................................................................................................................................................
Opium tincture .................................................................................................................................................................
Opium, powdered ............................................................................................................................................................
Opium, granulated ...........................................................................................................................................................
Oxymorphone ..................................................................................................................................................................
Noroxymorphone .............................................................................................................................................................
Tapentadol .......................................................................................................................................................................
The company plans to manufacture
the listed controlled substances as an
Active Pharmaceutical Ingredient (API)
for supply to its customers. In reference
to drug codes 7360 (Marihuana) and
7370 (Tetrahydrocannabinols), the
company plans to bulk manufacture
these drugs as synthetics. No other
activities for these drug codes are
authorized for this registration.
William T. McDermott,
Assistant Administrator.
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Bulk Manufacturer of Controlled
Substances Application: Kinetochem
LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Jkt 253001
The company plans to synthetically
manufacture drug codes 7360
(Marihuana) and 7370
(Tetrahydrocannabinols), in bulk for
distribution and sale to its customers.
No other activities for these drugs are
authorized for this registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020–23395 Filed 10–21–20; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Office of Federal Contract Compliance
Programs
RIN 1250–ZA01
Request for Information; Race and Sex
Stereotyping and Scapegoating
Office of Federal Contract
Compliance Programs
ACTION: Request for information
AGENCY:
The Office of Federal Contract
Compliance Programs (OFCCP) at the
Department of Labor seeks comments,
information, and materials from the
public relating to workplace trainings
that involve race or sex stereotyping or
SUMMARY:
Kinetochem LLC has applied
to be registered as a bulk manufacturer
of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
17:35 Oct 21, 2020
In
accordance with 21 CFR 1301.33(a), this
is notice that on October 5, 2020,
Kinetochem LLC, 111 W Cooperative
Way, Suite 310–B, Georgetown, Texas
78626, applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
SUPPLEMENTARY INFORMATION:
[Docket No. DEA–733]
VerDate Sep<11>2014
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before December 21, 2020. Such
persons may also file a written request
for a hearing on the application on or
before December 21, 2020.
DATES:
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
ADDRESSES:
[FR Doc. 2020–23396 Filed 10–21–20; 8:45 am]
SUMMARY:
INFORMATION listed below for further
drug information.
7360
7370
9053
9145
9301
9307
1100
1205
1724
7379
8501
9050
9120
9143
9150
9193
9300
9330
9333
9610
9620
9630
9639
9640
9652
9668
9780
Schedule
Drug
code
Controlled substance
Marihuana ......................
Tetrahydrocannabinols ..
PO 00000
Frm 00046
Fmt 4703
Schedule
7360
7370
Sfmt 4703
I
I
E:\FR\FM\22OCN1.SGM
22OCN1
]]>Agencies
[Federal Register Volume 85, Number 205 (Thursday, October 22, 2020)]
[Notices]
[Pages 67374-67375]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-23396]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-734]
Bulk Manufacturer of Controlled Substances Application: Noramco
Inc.
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Noramco Inc. has applied to be registered as a bulk
manufacturer of basic class(es) of controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before December 21,
2020. Such persons may also file a written request
[[Page 67375]]
for a hearing on the application on or before December 21, 2020.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on October 6, 2020, Noramco Inc. 500 Swedes Landing
Road, Wilmington, Delaware 19801-4417, applied to be registered as an
bulk manufacturer of the following basic class(es) of controlled
substance(s):
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Marihuana.......................... 7360 I
Tetrahydrocannabinols.............. 7370 I
Codeine-N-oxide.................... 9053 I
Dihydromorphine.................... 9145 I
Hydromorphinol..................... 9301 I
Morphine-N-oxide................... 9307 I
Amphetamine........................ 1100 II
Lisdexamfetamine................... 1205 II
Methylphenidate.................... 1724 II
Nabilone........................... 7379 II
Phenylacetone...................... 8501 II
Codeine............................ 9050 II
Dihydrocodeine..................... 9120 II
Oxycodone.......................... 9143 II
Hydromorphone...................... 9150 II
Hydrocodone........................ 9193 II
Morphine........................... 9300 II
Oripavine.......................... 9330 II
Thebaine........................... 9333 II
Opium extracts..................... 9610 II
Opium fluid extract................ 9620 II
Opium tincture..................... 9630 II
Opium, powdered.................... 9639 II
Opium, granulated.................. 9640 II
Oxymorphone........................ 9652 II
Noroxymorphone..................... 9668 II
Tapentadol......................... 9780 II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
as an Active Pharmaceutical Ingredient (API) for supply to its
customers. In reference to drug codes 7360 (Marihuana) and 7370
(Tetrahydrocannabinols), the company plans to bulk manufacture these
drugs as synthetics. No other activities for these drug codes are
authorized for this registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-23396 Filed 10-21-20; 8:45 am]
BILLING CODE P
